LEADER 01304nam2-2200397li-450 001 990000219530203316 005 20170419115709.0 010 $a3-540-55490-4 035 $a0021953 035 $aUSA010021953 035 $a(ALEPH)000021953USA01 035 $a0021953 100 $a20019920d1992----m--y0itay0103----ba 101 0 $aeng 102 $aGW 200 1 $aSchrodinger operators$ethe quantum mechanical many-body problem$eproceedings, Denmark 15 May-1 August 1991$fErik Balslev (ed.) 210 $aBerlin [etc.]$cSpringer-Verlag$dcopyr. 1992 215 $a264 p.$cill.$d25 cm 225 2 $aLecture notes in physics$v403 410 0$1001000315105$12001$aLecture notes in physics$v403 610 1 $acongressi$aaarhus$a1991 610 1 $ameccanica quantistica$acongressi$a1991 676 $a530.144 702 1$aBalslev,$bErik 801 $aSistema bibliotecario di Ateneo dell' Università di Salerno$gRICA 912 $a990000219530203316 951 $a530 LNP (403)$b14457/cbs$c530$d00224087 959 $aBK 969 $aSCI 979 $c19920215 979 $c20001110$lUSA01$h1714 979 $c20020403$lUSA01$h1630 979 $aPATRY$b90$c20040406$lUSA01$h1616 979 $aRSIAV7$b90$c20090626$lUSA01$h1319 996 $aSchrodinger operators$979898 997 $aUNISA LEADER 02780nam 2200445z- 450 001 9910261137903321 005 20210211 035 $a(CKB)4100000002484713 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54175 035 $a(oapen)doab54175 035 $a(EXLCZ)994100000002484713 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology 210 $cFrontiers Media SA$d2017 215 $a1 online resource (175 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-362-6 330 $aMycoplasma pneumoniae (Mp) is a major human pathogen that causes both upper and lower respiratory infections, and is one of the leading causes of community acquired pneumonia (CAP), accounting for 11-15% of CAP throughout the world. Additionally it is known to induce an inflammatory process which depends on several mechanisms such as virulence of Mp (lipoproteins, community acquired respiratory distress syndrome (CARDS) toxin, oxidative products) and host defenses (cellular immunity and humoral immunity). Although it is a common pathogen, the pathogenesis for Mp infections is not yet fully understood. From the clinical point of view, since the pioneer studies in the 1960s and 1970s on the clinical presentation of Mp associated disease, the diagnostics approaches have changed dramatically leading to a better understanding of the clinical presentation and new issues have emerged - such as antibiotics resistance. The purpose of this Frontiers ebook is to thoroughly review and discuss the clinical presentation in view of the improved diagnostics, microbiological and immunological analysis of Mp infections, with focus on the history of Mp, clinical features of disease, bacterial structure of Mp and mechanism of gliding, clinical and laboratory diagnostics, the role of lipoproteins and Toll-like receptor, CARDS toxin, subtyping of Mp isolates and genome analysis, macrolide resistance and treatment. 606 $aMedicine$2bicssc 610 $aclinical presentation antimicrobial resistance 610 $aepidemiology 610 $aMycoplasma pneumoniae 610 $aoutcome 610 $apathogenesis 610 $atreatment 615 7$aMedicine 700 $aTakashi Shimizu$4auth$01311261 702 $aRan Nir-Paz$4auth 702 $aTakeshi Saraya$4auth 702 $aAnnemarie Van Rossum$4auth 702 $aCecile Bebear$4auth 906 $aBOOK 912 $a9910261137903321 996 $aMycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology$93030068 997 $aUNINA